Regulatory Effects of Cannabidiol on Mitochondrial Functions: A Review

• Main Authors: John Zewen Chan, Robin Elaine Duncan
• Format: Article
• Language: English
• Published: MDPI AG 2021-05-01
• Series: Cells
• Subjects: cannabidiol; oxidative stress; electron transport chain; apoptosis; cannabidiol pharmacokinetics; mitochondrial epigenetics
• Online Access: https://www.mdpi.com/2073-4409/10/5/1251

Cannabidiol (CBD) is part of a group of phytocannabinoids derived from <i>Cannabis</i><i>sativa.</i> Initial work on CBD presumed the compound was inactive, but it was later found to exhibit antipsychotic, anti-depressive, anxiolytic, and antiepileptic effects. In recent decades, evidence has indicated a role for CBD in the modulation of mitochondrial processes, including respiration and bioenergetics, mitochondrial DNA epigenetics, intrinsic apoptosis, the regulation of mitochondrial and intracellular calcium concentrations, mitochondrial fission, fusion and biogenesis, and mitochondrial ferritin concentration and mitochondrial monoamine oxidase activity regulation. Despite these advances, current data demonstrate contradictory findings with regard to not only the magnitude of effects mediated by CBD, but also to the direction of effects. For example, there are data indicating that CBD treatment can increase, decrease, or have no significant effect on intrinsic apoptosis. Differences between studies in cell type, cell-specific response to CBD, and, in some cases, dose of CBD may help to explain differences in outcomes. Most studies on CBD and mitochondria have utilized treatment concentrations that exceed the highest recorded plasma concentrations in humans, suggesting that future studies should focus on CBD treatments within a range observed in pharmacokinetic studies. This review focuses on understanding the mechanisms of CBD-mediated regulation of mitochondrial functions, with an emphasis on findings in neural cells and tissues and therapeutic relevance based on human pharmacokinetics.